Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression

Biomedicine and Pharmacotherapy

Volumn 68, Issue 3, 2014, Pages 307-313

  Shen, Hua ^a   Liu, Jinyuan ^a   Wang, Rong ^a   Qian, Xu ^b   Xu, Ruitong ^a   Xu, Tongpeng ^a   Li, Qi ^b   Wang, Lin ^b   Shi, Zhumei ^b   Zheng, Jitai ^b   Chen, Qiudan ^b   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Fulvestrant; Gefitinib; Non small cell lung cancer; Resistance

Indexed keywords

FULVESTRANT; GEFITINIB; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; MIRNLET7 MICRORNA, HUMAN; QUINAZOLINE DERIVATIVE;

ARTICLE; CELL LINE; CELL PROLIFERATION; DISEASE MARKER; DRUG SENSITIVITY; FETUS; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE; ONCOGENE LET 7C; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; CELL SURVIVAL; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; HUMANS; LUNG NEOPLASMS; MICRORNAS; QUINAZOLINES; TRANSFECTION; UP-REGULATION;

EID: 84899477607     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.10.007     Document Type: Article

References (38)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Shepherd F.A., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
3. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
4. Kris M.G., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
5. Toyooka S., Kiura K., Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005, 352:2136.
6. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
7. Godin-Heymann N., Bryant I., Rivera M.N., Ulkus L., Bell D.W., Riese D.J., et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007, 67:7319-7326.
8. Xu R., Shen H., Guo R., Sun J., Gao W., Shu Y. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomed Pharmacother 2012, 66:384-389.
9. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62:2141-2150.
10. Marquez-Garban D.C., Pietras R.J. Estrogen-signaling pathways in lung cancer. Adv Exp Med Biol 2008, 617:281-289.
11. Shen H., Yuan Y., Sun J., Gao W., Shu Y.Q. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 2010, 64:88-92.
12. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65:1459-1470.
13. Lai E.C. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002, 30:363-364.
14. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
15. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27:5848-5856.
16. Kefas B., et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008, 68:3566-3572.
17. Tong A.W., Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?. Cancer Gene Ther 2008, 15:341-355.
18. Chen C., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Re 2005, 33:e179.
19. Wang X. A PCR-based platform for microRNA expression profiling studies. RNA 2009, 15:716-723.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
21. Howell A., Bergh J. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer. J Clin Onco 2010, 28:4548-4550.
22. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006, 13:689-706.
23. Woode D.R., Aiyer H.S., Sie N., Zwart A.L., Li L., Seeram N.P., et al. Effect of berry extracts and bioactive compounds on fulvestrant (ICI 182,780) sensitive and resistant cell lines. Int J Breast Cancer 2012, 147828.
24. Bogush T.A., Dudko E.A., Beme A.A., Bogush E.A., Kim A.I., Polotsky B.E., et al. Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc) 2010, 75:1421-1427.
25. Massarweh S., et al. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011, 129:819-827.
26. Carlson R.W., O'Neill A., Vidaurre T., Gomez H.L., Badve S.S., Sledge G.W. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2012, 133:1049-1056.
27. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
28. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
29. Hua S., Xiaotao X., Renhua G., Yongmei Y., Lianke L., Wen G., et al. Reduced miR-31 and let-7 maintain the balance between differentiation and quiescence in lung cancer stem-like side population cells. Biomed Pharmacother 2012, 66:89-97.
30. Zhu W., Shan X., Wang T., Shu Y., Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127:2520-2529.
31. Gao W., Lu X., Liu L., Xu J., Feng D., Shu Y. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012, 13:330-340.
32. Ali S., Ahmad A., Aboukameel A., Bao B., Padhye S., Philip P.A., et al. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett 2012, 319:173-181.
33. Xia X.M., Jin W.Y., Shi R.Z., Zhang Y.F., Chen J. Clinical significance and the correlation of expression between Let-7 and K-ras in non-small cell lung cancer. Oncol Lett 2010, 1:1045-1047.
34. Wang Q.Z., Lv Y.H., Gong Y.H., Li Z.F., Xu W., Diao Y., et al. Double-stranded Let-7 mimics, potential candidates for cancer gene therapy. J Physiol Biochem 2012, 68:107-119.
35. Gadgeel S.M., Wozniak A. Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non-Small-Cell Lung Cancer. Clin Lung Cancer 2013.
36. Janmaat M.L., Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A., Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006, 118:209-214.
37. Yamasaki F., et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007, 67:5779-5788.
38. Levy R., Biran A., Poirier F., Raz A., Kloog Y. Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA. PLoS One 2011, 6:e27490.